Trials / Completed
CompletedNCT00814060
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
A Single Dose Bioavailability Study of 2 New Tablet Formulations of Neratinib Compared With a Reference Capsule in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neratinib | HKI-272 |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-12-23
- Last updated
- 2012-05-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00814060. Inclusion in this directory is not an endorsement.